Evidence map›Paper›PMID 34121594›Full record

ArticleLeukemia & lymphoma2021

Body mass index and survival of patients with lymphoma.

Dai Chihara, Melissa C Larson, Dennis P Robinson, Carrie A Thompson, Matthew J Maurer, Carla Casulo, Priyanka Pophali, Brian K Link, Thomas M Habermann, Andrew L Feldman and 3 more

Open access · greenAbstract read
In one paragraph

Article in Leukemia & lymphoma, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 5 countries.

Dai ChiharaDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-1153-2294
Melissa C LarsonDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Dennis P RobinsonDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Carrie A ThompsonDepartment of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Matthew J MaurerDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-1867-0526
Carla CasuloDepartment of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Priyanka PophaliDepartment of Medicine, Division of Hematology, Oncology and Palliative Care, University of Wisconsin, Madison, WI, USA.ORCID 0000-0002-2410-9540
Brian K LinkDepartment of Internal Medicine, Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa Carver College of Medicine, Iowa City, IA, USA.
Thomas M HabermannDepartment of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Andrew L FeldmanDepartment of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic, Rochester, MN, USA.
Christopher R FlowersDepartment of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-9524-3990
James R CerhanDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Lindsay M MortonDepartment of Health and Human Services, Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0001-9767-2310
Department of Medical Sciences · BYMayo Clinic in Arizona · USNational Institutes of Health · USThe University of Texas MD Anderson Cancer Center · USUniversity of Iowa · USUniversity of Rochester Medical Center · USUniversity of Wisconsin–Madison · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
The Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI LENTZ, STEVEN R · 2002 to 2021
$45.7M
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study (Supplement)U01CA195568 · NCI · MAYO CLINIC ROCHESTER · PI CERHAN, JAMES R, FLOWERS, CHRISTOPHER R · 2015 to 2025
$22.1M
NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA097274NCI NIH HHS U01 CA195568
6 · The paper itself

Abstract

The impact of body mass index (BMI) on survival in lymphoma remains controversial. We leveraged a prospective cohort of lymphoma patients enrolled to SPORE Molecular Epidemiology Resource between 2002 and 2015 to assess the association of BMI before diagnosis, BMI at diagnosis, and BMI change over time with lymphoma-specific survival (LSS). A total of 4009 lymphoma patients (670 diffuse large B-cell lymphoma (DLBCL), 689 follicular lymphoma (FL), 1018 chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and 1632 other subtypes) were included. Significantly shorter LSS after diagnosis was observed for FL patients who were obese before diagnosis (HR: 3.02, 95%CI: 1.43-6.41,

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, FollicularLymphoma, Large B-Cell, DiffuseBody Mass IndexCohort StudiesHumansProspective Studiesbody mass indexCLL/SLLDiffuse large B-cell lymphomafollicular lymphomasurvival

Identifiers

PMID34121594
PMCPMC8771423
OpenAlexW3170069301

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.